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Abstract
Background: Studies conducted in Swedish populations have shown that men with lowest prostate-specific antigen (PSA)
levels at ages 44–50 years and 60 years have very low risk of future distant metastasis or death from prostate cancer. This
study investigates benefits and harms of screening strategies stratified by PSA levels.
Methods: PSA levels and diagnosis patterns from two microsimulation models of prostate cancer progression, detection, and
mortality were compared against results of the Malmö Preventive Project, which stored serum and tracked subsequent prostate
cancer diagnoses for 25 years. The models predicted the harms (tests and overdiagnoses) and benefits (lives saved and life-years
gained) of PSA-stratified screening strategies compared with biennial screening from age 45 years to age 69 years.
Results: Compared with biennial screening for ages 45–69 years, lengthening screening intervals for men with PSA less than
1.0 ng/mL at age 45 years led to 46.8–47.0% fewer tests (range between models), 0.9–2.1% fewer overdiagnoses, and 3.1–3.8%
fewer lives saved. Stopping screening when PSA was less than 1.0 ng/mL at age 60 years and older led to 12.8–16.0% fewer
tests, 5.0–24.0% fewer overdiagnoses, and 5.0–13.1% fewer lives saved. Differences in model results can be partially explained
by differences in assumptions about the link between PSA growth and the risk of disease progression.
Conclusion: Relative to a biennial screening strategy, PSA-stratified screening strategies investigated in this study substan-
tially reduced the testing burden and modestly reduced overdiagnosis while preserving most lives saved. Further research is
needed to clarify the link between PSA growth and disease progression.
It has long been understood that controlling the harm–benefit
trade-off of prostate-specific antigen (PSA) screening is critical
for its sustainability. Strategies for reducing harms while pre-
serving benefits include screening less frequently, using higher
thresholds for biopsy referral in older men, and tailoring screen-
ing algorithms by PSA level (1–15).
The recommendation to stratify screening by PSA level is
largely based on studies that stored ethylenediamine tetraacetic
acid plasma in an unscreened cohort of Swedish men aged 44–
60 years in the 1980s (4,11,12,16,17). Prostate cancer cases diag-
nosed up to 25 years later had statistically significantly higher
PSA levels at their baseline blood draw than those not diag-
nosed. There was also a strong association between baseline
PSA and prostate cancer mortality: 44% of prostate cancer
deaths occurred in men with PSA in the top 10% of the PSA dis-
tribution at ages 44–49 years (12). In addition, only 0.2% of men
with PSA below 1.0 ng/mL at age 60 years died from prostate
cancer within 25 years (11). Other studies, including screened
and unscreened cohorts, have confirmed that baseline PSA pre-
dicts the risk of future prostate cancer diagnosis or prostate
cancer death (5–7,13,15,18). These studies have motivated pro-
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level. However, the implications of such stratified policies for
clinically important outcomes, such as prostate cancer deaths
or overdiagnosis, compared with current practices have not
been evaluated. Despite this, some guidelines are already incor-
porating PSA-stratified screening. The European Association of
Urology guideline states that targeting men at a higher risk of
prostate cancer (older than age 50 years, or with PSA >1.0 ng/mL
at age 40 years, or >2.0 ng/mL at age 60 years) might reduce the
number of unnecessary biopsies (19). The American Urological
Association guideline suggests that baseline PSA may be used
to guide alternative screening strategies that screen less fre-
quently (20).
Some studies have attempted to evaluate the relative harms
and benefits of different PSA-based screening strategies.
Multiple studies using data from the European Randomized
Study of Screening for Prostate Cancer support using a screen-
ing interval of 8 years in men with initial PSA levels below
1.0 ng/mL (8–10,14). A modeling study showed that switching
from annual to biennial screening when PSA is less than
2.5 ng/mL did not affect the probabilities of detection and over-
diagnosis (2). Although it is believed that screening intervals
longer than 2 years delay the diagnosis of aggressive cancers yet
still detect most indolent cancers, there are few studies with
quantitative predictions.
This study analyzes harm–benefit trade-offs associated with
lengthening the screening interval when PSA is below 1.0 ng/mL
at age 45 or 50 years or discontinuing screening when PSA is be-
low 1.0 ng/mL at age 60 years. We focus specifically on how
these policies are likely to affect clinically important outcomes
like lives saved and overdiagnosis. Ultimately, we aim to deter-
mine how stratified screening might change the balance be-
tween harms and benefits of screening compared with using a
single screening strategy for the entire population.
Methods
Microsimulation Models
Two microsimulation models—the Erasmus University Medical
Center-MIcrosimulation SCreening ANalysis (Erasmus-MISCAN)
model and the Fred Hutchinson Cancer Research Center (FHCRC)
model—were used. The models were independently developed
within the Cancer Intervention and Surveillance Modeling
Network to describe the natural history of prostate cancer and to
investigate disease progression and survival given screening and
primary treatment. The two models have been described previ-
ously (https://resources.cisnet.cancer.gov/registry) (2,3,21,22). In
both models, a virtual population of individuals can develop can-
cer and progress through a sequence of states defined by clinical
stages and Gleason grades. The Erasmus-MISCAN model permits
grade progression after onset whereas the FHCRC model does
not; rather, the FHCRC model allocates a specific grade at onset,
with older men more likely to be assigned high-grade disease.
Both models include individual-specific PSA trajectories that ac-
celerate after disease onset. The FHCRC model links PSA growth
(increasing levels of PSA in blood) with disease progression;
patients with high PSA doubling times are more likely to progress
slowly. The Erasmus-MISCAN model does not link PSA growth
with disease progression; in this model, cases with high PSA dou-
bling times are as likely to progress quickly or slowly (see
Supplementary Materials available online). If a PSA level at a des-
ignated screening age exceeds a specified threshold for referral to
biopsy and disease is present, it is diagnosed depending on the
biopsy frequency and sensitivity to detect latent cancer. The
model states and primary determinants of state transitions are
presented in Figure 1.
Both models generate prostate cancer survival from clinical
diagnosis in the absence of screening or localized treatment
benefit (23) based on Cox regression models fit to Surveillance,
Epidemiology, and End Results (SEER) survival data
(Supplementary Materials available online) before the wide-
spread adoption of PSA screening. This survival is improved for
localized cases who receive radical prostatectomy, or radiation
therapy, using a hazard ratio of 0.56 (24). Distributions of treat-
ments depending on age, Gleason score, and stage are based on
multinomial regression models fit to SEER cases diagnosed in
the year 2012, just before the US Preventive Services Task Force
recommendation against PSA screening (25).
The mortality benefit of PSA screening is modeled via a cure
probability that increases with the lead time. The lead time is
the interval by which detection of the cancer is advanced by
screening and is produced as an individual-level output under
any specified screening policy (26). In both models, the cure
probability is calibrated to reproduce the mortality rate ratio in
the European Randomized Study of Screening for Prostate
Cancer (26). Deaths due to noncancer causes are generated in-
dependently based on US life tables. The primary harm of PSA
screening is overdiagnosis, which is the diagnosis of cancer that
would not have been diagnosed during the patient’s lifetime in
the absence of screening.
Calibration
Malmö Preventive Project data provided to us for this study con-
sisted of summary tables of PSA quantiles and 25-year predicted
probabilities of diagnosis given log PSA levels for men ages
44–50 years at the time of blood draw. Individual PSA levels and
25-year case-control status for men age 60 years at the time of
blood draw were also provided (see Supplementary Materials,
available online).
To compare modeled PSA distributions at ages 44–50 years
and age 60 years with the Malmö data, we calculated densities
of individual PSA levels simulated by the models at the corre-
sponding ages. To compare probabilities of diagnosis within
25 years of these ages predicted by the models and by using
Malmö data, we fitted logistic regressions of 25-year case status
to log observed and modeled PSA levels.
In the FHCRC model, previously estimated PSA growth and
natural history parameter values reasonably approximated the
Malmö results over the bulk of the range of observed PSA values
and were used without additional calibration (21). In the
Erasmus-MISCAN model, the PSA growth parameters were rees-
timated in combination with the parameters for onset of pros-
tate cancer by calibrating to the PSA distribution in the Malmö
study and to SEER incidence in the period 1990–2002 (see
Supplementary Materials, available online). Since opportunistic
screening was increasing during the late 1990s in the Malmö
area (27,28), predicted probabilities of diagnosis from the Malmö
study until 1995 and 2000 (15 and 20 years of follow-up) for the
44- to 50-year-olds provided by the Malmö study investigators,
were also compared with the model predictions.
Screening Strategies
Using the calibrated models, we simulated cohorts of men in the
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years. We implemented the following screening strategies:
screening up to age 69 years with 2-year intervals; lengthening
the screening interval to 8 years for baseline PSA less than 1.0 ng/
mL but decreasing again to 2 years when PSA is greater than
1.0 ng/mL at a later screen; stopping screening when PSA is less
than 1.0 ng/mL at age 60 years and older; or a combination of the
last two strategies. For reference, we also implemented strategies
that stop screening all men at age 60 years. In all strategies, a PSA
threshold of 4.0 ng/mL was used. To evaluate the optimal strat-
egy, a 100% attendance rate to each screen was specified, and
positive screens were followed with a biopsy compliance and sen-
sitivity of 100%. For each screening policy, we projected the num-
ber of tests conducted, cancers diagnosed (screen and clinically
detected), overdiagnoses, lives saved, and life-years gained.
Results
Comparison of Calibrated Models With Malmö Results
The calibrated models reasonably replicated the PSA distribu-
tions at ages 44–50 years and at age 60 years in the Malmö study
(Figures 2 and 3). The median PSA values in the models were
within 0.2 ng/mL of the median in Malmo at ages 44–50 years
and 60 years. The 25-year probability of diagnosis in the absence
of screening predicted by the FHCRC model slightly overpre-
dicted the Malmö results, particularly in the upper tail of the
PSA distribution at ages 44–50 years, where data were sparse. A
similar pattern was observed in the comparison of the 15- and
20-year FHCRC predictions with the corresponding Malmö
results (Supplementary Materials, available online). The 25-year
probability of diagnosis in the absence of screening predicted by
the Erasmus-MISCAN model considerably underpredicted the
Malmö results, but the 15- and 20-year predictions were much
closer to the observed data.
Predictions of Calibrated Models Under Stratified
Screening
The models projected that screening 10 000 men ages 45–69
years biennially would require more than 110 000 screens, yield
277 (Erasmus-MISCAN model) to 348 (FHCRC model) overdiag-
noses, save 110 (Erasmus-MISCAN model) to 160 (FHCRC model)
lives, and gain 921 (Erasmus-MISCAN model) to 1312 (FHCRC
model) life-years relative to no screening (Table 1). The pre-
dicted reduction in prostate cancer mortality (assuming 100%
adherence and biopsy compliance) was 38.6% for the Erasmus-
MISCAN model and 53.3% for the FHCRC model compared with
a no-screening scenario.
Relative to this nonstratified policy, the Erasmus-MISCAN
model predicted that lengthening the screening interval from 2
to 8 years when PSA is less than 1.0 ng/mL at age 45 years would
reduce the screen tests by 46.8%, overdiagnoses by 2.1%, and
lives saved by 3.8%. The FHCRC model predicted a 47.0% reduc-
tion in screen tests, 0.9% reduction in overdiagnosis, and 3.1%
reduction in lives saved.
Relative to the same nonstratified policy, the Erasmus-
MISCAN model predicted that early cessation when PSA is less
than 1.0 ng/mL at age 60 years and older would decrease
Figure 1. The structures of the Fred Hutchinson Cancer Research Center (FHCRC) model and the Erasmus University Medical Center-MIcrosimulation SCreening
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overdiagnoses by 24.0% and lives saved by 13.1%. The FHCRC
model projected a modest impact of early cessation with a 5.5%
reduction in overdiagnosis and a 5.0% reduction in lives saved
relative to the nonstratified biennial screening policy.
When combining PSA-stratified screening intervals at age 45
years and early cessation at age 60 years, the Erasmus-MISCAN
model projected a 52.2% reduction in screening tests, a 24.4% re-
duction in overdiagnoses, and a 14.8% reduction in lives saved. The
FHCRC model projected a 51.1% reduction in screening tests, a 5.7%
reduction in overdiagnoses, and a 7.5% reduction in lives saved.
The ratio of overdiagnoses to lives saved was 2.2 for all strat-
egies for the FHCRC model. The Erasmus-MISCAN model pre-
dicted a slightly higher ratio of overdiagnosis to lives saved for
biennial screening for all ages 45–69 years (ratio¼ 2.5) and for
lengthening the screening interval from 2 to 8 years when PSA
is less than 1.0 ng/mL (ratio¼ 2.6).
Finally, the models predicted that discontinuing screening at
age 60 years for everyone would greatly reduce overdiagnoses
(by 79.3–81.7%) but would save substantially fewer lives (47.5–
55.4%) and life-years gained (34.3–33.6%) compared with screen-
ing until age 69 years.
The results for strategies starting at age 50 years were compa-
rable with those for strategies starting at age 45 years (Table 2).
Discussion
This study used modeling to explore the likely policy implica-
tions of stratifying prostate cancer screening strategies by PSA
Figure 2. Observed prostate-specific antigen (PSA) distributions and predicted 25-year risk of diagnosis based on empirical data from the Malmö Preventive Project
(N¼10 357) and corresponding model projections in the absence of screening for men ages 44–50 years. Both empirical and model projections are derived from logistic
regression models for event of disease diagnosis over 25 years in either the empirical or the modeled data. Erasmus-MISCAN ¼ Erasmus University Medical Center-
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level. Such approaches have been strongly suggested by retro-
spective data from the Malmö Preventive Project and other
cohorts on disease incidence in relation to baseline PSA, but
their impact on clinically important downstream outcomes has
never been prospectively evaluated.
Modeling is of value in this setting because it enables the
translation of observed data on cumulative disease incidence
given PSA into projected harm–benefit trade-offs for specific
stratified screening policies. The results show that the proximal
effect of stratifying screening by PSA level is a marked reduction
in the number of tests by 50% compared with a biennial screen-
ing strategy for all men.
Although the models suggest that stratified screening is
likely to affect overdiagnoses and lives saved, quantitative
results appear to depend on the specific model used. The
Erasmus-MISCAN and FHCRC models make different assump-
tions about disease natural history and, in particular, about
how PSA levels are linked with progression. This may explain
why the models produce different overdiagnosis results under
PSA-stratified screening at age 60 years. At this age, most men
with PSA less than 1.0 ng/mL are cancer free. In the Erasmus-
MISCAN model, slowly progressing and potentially overdiag-
nosed cancers that develop after this point may have either fast
or slow PSA growth. The potential overdiagnoses with fast PSA
growth will be screen detected if screening continues beyond
age 60 years and are prevented when screening stops early.
Therefore, early cessation for low PSA leads to a reduction in
overdiagnosis in the Erasmus-MISCAN model. In the FHCRC
model, slowly progressing and potentially overdiagnosed can-
cers that develop after age 60 years generally have slow PSA
Figure 3. Observed prostate-specific antigen (PSA) distributions and predicted 25-year risk of diagnosis based on empirical data from the Malmö Preventive Project
(N¼1162) and corresponding model projections in the absence of screening for men aged 60 years. Both empirical and model projections are derived from logistic
regression models for event of disease diagnosis over 25 years in either the empirical or the modeled data. Erasmus-MISCAN ¼ Erasmus University Medical Center-
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growth. The potential overdiagnoses with slow PSA growth will
generally not be screen detected even if screening continues be-
cause they will tend to remain below the screen-positive
threshold of 4.0 ng/mL until after age 69 years when screening
stops for all men. Therefore, early cessation for men with low
PSA levels does not lead to a meaningful reduction in overdiag-
nosis in the FHCRC model.
Overdiagnoses avoided with early cessation are 60 of 10 000
men for the Erasmus-MISCAN model and 19 of 10 000 for the
FHCRC model. These results are both lower than the estimate of





Screening ages 45–69 y every 2 y
Screening ages





(b) 8 y if PSA <1.0 ng/mL,
change to 2 y if PSA >1.0 ng/
mL,
No. (%‡)
(c) Stop if PSA <1.0





Tests 0 116 172 61 751 (46.8) 97 533 (16.0) 55 555 (52.2) 76 273 (34.3)
Cancers detected 966 1270 1263 (0.6) 1196 (5.8) 1194 (6.0) 1020 (19.7)
Screen detected 0 740 717 (3.1) 591 (20.1) 582 (21.3) 202 (72.7)
Overdiagnosed 0 277 271 (2.1) 211 (24.0) 209 (24.4) 51 (81.7)
Lives saved† 0 110 106 (3.8) 95 (13.1) 94 (14.8) 49 (55.4)
Life-years gained 0 921 881 (4.4) 850 (7.6) 826 (10.3) 571 (38.0)
Overdiagnosis per life saved 2.5 2.6 2.2 2.2 1.0
FHCRC
Tests 0 112 849 59 846 (47.0) 98 379 (12.8) 55 233 (51.1) 74 986 (33.6)
Cancers detected 1130 1479 1476 (0.2) 1460 (1.3) 1459 (1.4) 1203 (18.7)
Screen detected 0 1115 1108 (0.6) 1065 (4.5) 1060 (4.9) 424 (62.0)
Overdiagnosed 0 348 345 (0.9) 329 (5.5) 328 (5.7) 72 (79.3)
Lives saved† 0 160 155 (3.1) 152 (5.0) 148 (7.5) 84 (47.5)
Life-years gained 0 1312 1251 (4.6) 1270 (3.2) 1217 (7.2) 882 (32.8)
Overdiagnosis per life saved – 2.2 2.2 2.2 2.2 0.9
*All results are given per 10 000 men, followed until age 85 years. Erasmus-MISCAN ¼ Erasmus University Medical Center-MIcrosimulation SCreening ANalysis; FHCRC
¼ Fred Hutchinson Cancer Research Center; PSA ¼ prostate-specific antigen.
†In the absence of screening, the Erasmus-MISCAN model predicted 285 prostate cancer deaths, the FHCRC model 300.
‡The percentages compare the results with the no-stratification results (a) screening ages 45–69 years every 2 years.













(b) 8 y if PSA <1.0 ng/
mL, change to 2 y if
PSA >1.0 ng/mL,
No. (%‡)
(c) Stop if PSA <1.0 ng/





Tests 0 87 959 50 473 (42.6) 68 458 (22.2) 46 716 (46.9) 47 142 (46.4)
Cancers detected 966 1231 1227 (0.4) 1162 (5.6) 1212 (1.6) 1007 (18.2)
Screen detected 0 658 642 (2.4) 513 (22.0) 612 (7.0) 157 (76.1)
Overdiagnosed 0 243 239 (1.7) 180 (25.7) 219 (9.6) 39 (83.7)
Lives saved† 0 101 97 (3.4) 85 (15.2) 94 (6.4) 39 (61.0)
Life-years gained 0 782 757 (3.2) 702 (10.2) 748 (4.4) 408 (47.9)
Overdiagnosis per life saved 2.4 2.5 2.1 2.3 1
FHCRC
Tests 0 85 078 50 050 (41.2) 69 625 (18.2) 48 110 (43.5) 46 233 (45.7)
Cancers detected 1130 1440 1439 (0.1) 1422 (1.3) 1433 (0.5) 1188 (17.5)
Screen detected 0 1039 1034 (0.5) 987 (5.0) 1020 (1.8) 362 (65.2)
Overdiagnosed 0 310 308 (0.6) 291 (6.1) 302 (2.6) 57 (81.6)
Lives saved† 0 152 149 (2.0) 143 (5.9) 147 (3.3) 72 (52.6)
Life-years gained 0 1239 1197 (3.4) 1189 (4.0) 1188 (4.1) 758 (38.8)
Overdiagnosis per life saved – 2.0 2.1 2.0 2.1 0.8
*All results are given per 10 000 men, followed until age 85 years. Erasmus-MISCAN ¼ Erasmus University Medical Center-MIcrosimulation SCreening ANalysis; FHCRC
¼ Fred Hutchinson Cancer Research Center; PSA ¼ prostate-specific antigen.
†In the absence of screening, the Erasmus-MISCAN model predicted 285 prostate cancer deaths, the FHCRC model 300.
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171 of 10 000 overdiagnoses avoided over 15 years from early
cessation based on comparing 15-year incidence in the screen-
ing arm of the Göteborg trial to incidence from the unscreened
Malmö cohort, conditional on PSA level at age 60 years (4).
A partial reason for the discrepancy may be that this study uses
excess incidence over 15 years as a proxy for overdiagnosis,
whereas the models explicitly calculate the frequency of overdi-
agnosis in the simulated cohorts under the different screening
policies.
There are also differences between the models and empirical
studies with respect to the risk of prostate cancer–specific death
in men with low PSA. In the mostly unscreened Malmö cohort,
the death rate for men with PSA less than 1.0 ng/mL at age 60
years was 20 per 10 000 by age 85 years (11). In contrast, the
models project a higher risk of prostate cancer–specific death for
these men: 85 (FHCRC model) and 140 (Erasmus-MISCAN model)
per 10 000 men by age 85 years. Because models project a higher
risk of death for men with PSA less than 1.0 ng/mL at age 60 years
than that estimated in the Malmö study, they also project a more
pronounced impact on lives saved associated with stopping
screening when PSA is less than 1.0 ng/mL at age 60 years.
Although using two models that simultaneously approxi-
mate high-dimensional empirical data from two sources creates
some robustness around the main result, it also leaves the pri-
mary scientific question partially unanswered. The models con-
cur that a key effect of stratifying screening by PSA level is a
large reduction in testing burden. The models also agree about
the effects of lengthening screening intervals for men with low
PSA. The models predict quantitatively different effects of early
cessation for men with low PSA at age 60 years and older.
Nevertheless, the models agree qualitatively across all settings
that PSA-stratified strategies will lead to modest reductions in
both overdiagnoses and lives saved, and therefore these strate-
gies are ready to be evaluated in a clinical setting.
Limitations of this study include the necessary simplification
of biology represented by disease models and the difficulty in
quantifying uncertainty around model projections. Discrepancies
between the empirical and model-predicted probabilities of pros-
tate cancer diagnosis may be due at least in part to the unknown
proportion of men who received screening tests in the later years
in Sweden, which probably increased the probability of diagnosis
in the observed data, and to the low number of men with base-
line PSA greater than 1.5 ng/mL, leading to uncertainty in the pre-
dicted probability of diagnosis for men with PSA levels in this
range. Several assumptions were made to simplify comparisons
across strategies. We assumed 100% of men received biopsy after
a positive PSA test. In practice, receipt of biopsy after a positive
PSA test depends on patient risk factors, preferences, and comor-
bidities. Lower receipt of biopsy, particularly in low-risk men, is
likely to reduce overdiagnosis more than it reduces lives saved
under both stratified and nonstratified strategies. We also as-
sumed receipt of definitive treatment based on patient age and
tumor grade. In practice, genomic profiling, imaging, and other
technologies can guide treatment selection. Our results with the
greatest uncertainty concern overdiagnosis, which cannot be ac-
curately predicted for individual patients.
An additional benefit of screening is the reduction in metas-
tases at diagnosis and after diagnosis (29). Effects of risk-
stratified screening on this endpoint, and implications for qual-
ity of life, should be examined in future research.
Less intensive PSA screening in men with low PSA levels can
substantially reduce the testing burden. The specific quantitative
impact on overdiagnosis and lives saved is sensitive to the model
used, but both models project that stratifying screening by PSA
level is expected to reduce overdiagnosis by a modest amount
while preserving the majority of the benefit of screening.
Depending on how these harms and benefits are valued, our
results confirm that PSA-based stratification could lead to more
efficient use of the PSA test in early detection of prostate cancer.
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